Innovation, Science & Economic Development Canada regarding export provisions of the Patent Act (pharmaceuticals).
Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) and re-negotiation of NAFTA with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
Legislative Proposal, Bill or Resolution, Regulation
Health Canada regarding the Cannabis Act (C-45) and its Regulations for medicinal cannabis
Policies or Program
Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
Health Canada, Innovation, Science & Economic Development Canada and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
Regulation
As a member company, participation in the Canadian Generic Pharmaceutical Association's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to the extended period of data exclusivity, as well as further proposed amendments to these regulations.
Health Canada regarding regulation about Requirement for reporting of drug shortages.
Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.